晚期肝细胞癌系统治疗及序贯选择的系统综述与网状Meta分析
该研究基于14项低偏倚风险的3期试验,采用网状Meta分析比较晚期肝细胞癌不同系统治疗的疗效。一线治疗中,阿替利珠单抗联合贝伐珠单抗相比仑伐替尼、索拉非尼和纳武利尤单抗显著改善生存;难治性 setting 中,瑞戈非尼和卡博替尼相比安慰剂有OS获益,AFP≥400 ng/mL患者中瑞戈非尼、卡博替尼和雷莫西尤单抗均显示PFS和OS获益。
要点
- 阿替利珠单抗联合贝伐珠单抗为晚期HCC一线标准治疗。
- 瑞戈非尼和卡博替尼是难治性患者的优选方案。
- AFP≥400 ng/mL者可考虑雷莫西尤单抗作为额外选择。
核心结论
- 阿替利珠单抗联合贝伐珠单抗被推荐为晚期肝细胞癌一线标准治疗。
- 瑞戈非尼和卡博替尼是难治性患者的优选方案,雷莫西尤单抗为AFP≥400 ng/mL者的额外选择。
研究设计与样本
- 系统综述与网状Meta分析,纳入14项低偏倚风险的3期试验。
- 一线治疗8项试验共6290例患者,年龄18至89岁。
- 二线治疗5项试验共2653例患者,年龄18至91岁。
- 检索数据库自建库至2020年3月的摘要和全文。
主要发现
- 一线治疗中,阿替利珠单抗联合贝伐珠单抗相比仑伐替尼(HR 0.63;95% CI 0.44-0.89)、索拉非尼(HR 0.58;95% CI 0.42-0.80)和纳武利尤单抗(HR 0.68;95% CI 0.48-0.98)更具优势。
- 难治性 setting 中,所有研究药物相比安慰剂均有PFS获益。
- 难治性 setting 中,仅瑞戈非尼(HR 0.62;95% CI 0.51-0.75)和卡博替尼(HR 0.76;95% CI 0.63-0.92)相比安慰剂有OS获益。
- AFP≥400 ng/mL患者中,瑞戈非尼、卡博替尼和雷莫西尤单抗相比安慰剂有PFS和OS获益,但活性药物间无优越性。
临床怎么用
- 一线治疗优先选择阿替利珠单抗联合贝伐珠单抗。
- 难治性患者可选用瑞戈非尼或卡博替尼。
- AFP≥400 ng/mL者可考虑雷莫西尤单抗。
局限性
- 缺乏头对头比较,网状Meta分析基于间接比较。
- 未来需关注既往VEGFi/CPI暴露患者的联合治疗和最佳策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The treatment landscape for advanced hepatocellular carcinoma (HCC) has recently changed and become relatively confusing. Head-to-head comparisons between most of the available agents have not been performed and are less likely to be examined in a prospective fashion in the future. Therefore, a network meta-analysis (NMA) is helpful to compare different agents from across different trials. OBJECTIVE: To evaluate comparative effectiveness of different systemic treatments in advanced patients with HCC across lines of therapy. DATA SOURCES: We searched various databases for abstracts and full-text articles published from database inception through March 2020. STUDY SELECTION: We included phase 3 trials evaluating different vascular endothelial growth factor inhibitors (VEGFis), checkpoint inhibitors (CPIs), or their combinations in advanced HCC, in the first-line or refractory setting. DATA EXTRACTION AND SYNTHESIS: The reporting of this systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. The overall effect was pooled using the random effects model. MAIN OUTCOMES AND MEASURES: Outcomes of interest included overall (OS) and progression-free survival (PFS). FINDINGS: Fourteen trials (8 in the first-line setting and 6 in the second-line setting) at low risk of bias were included. The 8 trials in the first-line setting encompassed a total of 6290 patients, with an age range of 18 to 89 years. The 5 trials included in the second-line analysis encompassed a total of 2653 patients, with an age range of 18 to 91 years. Network meta-analysis showed the combination of atezolizumab and bevacizumab was superior in patients with HCC treated in the first-line setting compared with lenvatinib (HR, 0.63; 95% CI, 0.44-0.89), sorafenib (HR, 0.58; 95% CI, 0.42-0.80), and nivolumab (HR, 0.68; 95% CI, 0.48-0.98). In the refractory setting, NMA showed that all studied drugs had PFS benefit compared with placebo. However, this only translated into OS benefit with regorafenib (HR, 0.62; 95% CI, 0.51-0.75) and cabozantinib (HR, 0.76; 95% CI, 0.63-0.92) compared with placebo. In the NMA of patients with α-fetoprotein (AFP) levels of 400 ng/mL or greater, regorafenib, cabozantinib, and ramucirumab showed PFS and OS benefit compared with placebo with no superiority of an active drug compared with any others. CONCLUSIONS AND RELEVANCE: This systematic review and NMA of 14 trials found that atezolizumab and bevacizumab in combination is now considered the standard of care in the first-line setting in patients with advanced HCC. Regorafenib and cabozantinib are preferred options in refractory patients, with ramucirumab as an additional option in those with levels of AFP of 400 ng/mL or higher. Future trials should focus on other potential combinations and best treatment strategy in patients with prior VEGFi/CPI exposure.
引用
- Sonbol MB, Riaz IB, Naqvi SAA, et al. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020. PMID: 33090186. doi:10.1001/jamaoncol.2020.4930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。